select a format

Single User License
USD 125 INR 8106
Site License
USD 250 INR 16213
Corporate User License
USD 375 INR 24319

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Achillion Pharmaceuticals, Inc. (ACHN)-Financial and Strategic SWOT Analysis Review

Achillion Pharmaceuticals, Inc. (ACHN)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH27007FSA
  • |
  • Pages: 54
  • |
  • August 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Achillion Pharmaceuticals, Inc. (ACHN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system disorders. The company focuses at developing life-saving medicines to patients with rare diseases. It is developing oral antiviral therapy for chronic hepatitis C (HCV) and a platform of potent and specific complement inhibitors. Achillion intends to develop and commercialize factor D inhibitors for rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), C3 Glomerulopathy (C3G), dry age-related macular degeneration (dry AMD) and chronic obstructive pulmonary disease (COPD). Achillion is headquartered in New Haven, Connecticut, the US.

Achillion Pharmaceuticals, Inc. Key Recent Developments

Aug 04, 2016: Achillion Reports Second Quarter 2016 Financial Results

May 03, 2016: Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs

Feb 25, 2016: Achillion Reports 2015 Fourth Quarter and Year-End Financial Results

Feb 03, 2016: Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs

Jan 04, 2016: Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Achillion Pharmaceuticals, Inc.-Key Facts 6

Achillion Pharmaceuticals, Inc.-Key Employees 7

Achillion Pharmaceuticals, Inc.-Key Employee Biographies 8

Achillion Pharmaceuticals, Inc.-Major Products and Services 10

Achillion Pharmaceuticals, Inc.-Pharmaceutical Pipeline Products Data 11

Achillion Pharmaceuticals, Inc., Pipeline Products by Therapy Area 11

Achillion Pharmaceuticals, Inc., Pipeline Products by Development Phase 12

Achillion Pharmaceuticals, Inc.-History 14

Achillion Pharmaceuticals, Inc.-Company Statement 17

Achillion Pharmaceuticals, Inc.-Locations And Subsidiaries 19

Head Office 19

Section 2-Company Analysis 20

Achillion Pharmaceuticals, Inc.-Business Description 20

Achillion Pharmaceuticals, Inc.-Corporate Strategy 21

Achillion Pharmaceuticals, Inc.-SWOT Analysis 22

SWOT Analysis-Overview 22

Achillion Pharmaceuticals, Inc.-Strengths 22

Strength-Focused Research and Development Activities 22

Strength-Intellectual Property 22

Strength-Strategic Alliances 22

Achillion Pharmaceuticals, Inc.-Weaknesses 23

Weakness-Weak Financial Position 23

Achillion Pharmaceuticals, Inc.-Opportunities 24

Opportunity-Product Pipeline 24

Opportunity-Fast Track Designation 24

Opportunity-Changing Demographics 24

Achillion Pharmaceuticals, Inc.-Threats 25

Threat-Intense Competition 25

Threat-Lack of Manufacturing Facilities 25

Threat-Tightening of the FDA's Regulatory 25

Achillion Pharmaceuticals, Inc.-Key Competitors 26

Section 3-Company Financial Ratios 27

Financial Ratios-Capital Market Ratios 27

Financial Ratios-Annual Ratios 28

Performance Chart 29

Financial Performance 29

Financial Ratios-Interim Ratios 30

Financial Ratios-Ratio Charts 31

Section 4-Company's Lifesciences Financial Deals and Alliances 32

Achillion Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 32

Achillion Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 33

Achillion Pharmaceuticals, Inc., Recent Deals Summary 34

Section 5-Company's Recent Developments 35

Aug 04, 2016: Achillion Reports Second Quarter 2016 Financial Results 35

May 03, 2016: Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs 37

Feb 25, 2016: Achillion Reports 2015 Fourth Quarter and Year-End Financial Results 39

Feb 03, 2016: Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs 41

Jan 04, 2016: Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer 42

Dec 16, 2015: Achillion Appoints Dr. Frank Verwiel to Board of Directors 43

Nov 05, 2015: Achillion Reports Third Quarter And Nine Month 2015 Financial Results 44

Nov 05, 2015: Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology Detailing Novel Results With Factor D Inhibitors 46

Aug 10, 2015: Achillion Reports Second Quarter and Six Month 2015 Financial Results 47

May 07, 2015: Achillion Reports First Quarter 2015 Financial Results 49

Section 6-Appendix 50

Methodology 50

Ratio Definitions 50

About GlobalData 54

Contact Us 54

Disclaimer 54

List of Figures

Achillion Pharmaceuticals, Inc., Pipeline Products by Therapy Area 11

Achillion Pharmaceuticals, Inc., Pipeline Products by Development Phase 12

Achillion Pharmaceuticals, Inc., Performance Chart (2011-2015) 29

Achillion Pharmaceuticals, Inc., Ratio Charts 31

Achillion Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 32

Achillion Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 33

List of Tables

Achillion Pharmaceuticals, Inc., Key Facts 6

Achillion Pharmaceuticals, Inc., Key Employees 7

Achillion Pharmaceuticals, Inc., Key Employee Biographies 8

Achillion Pharmaceuticals, Inc., Major Products and Services 10

Achillion Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 11

Achillion Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 12

Achillion Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 13

Achillion Pharmaceuticals, Inc., History 14

Achillion Pharmaceuticals, Inc., Key Competitors 26

Achillion Pharmaceuticals, Inc., Ratios based on current share price 27

Achillion Pharmaceuticals, Inc., Annual Ratios 28

Achillion Pharmaceuticals, Inc., Interim Ratios 30

Achillion Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 32

Achillion Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 33

Achillion Pharmaceuticals, Inc., Recent Deals Summary 34

Currency Codes 50

Capital Market Ratios 50

Equity Ratios 51

Profitability Ratios 51

Cost Ratios 52

Liquidity Ratios 52

Leverage Ratios 53

Efficiency Ratios 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Achillion Pharmaceuticals, Inc., SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com